Helixon
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody 2025-07-10 19:00
Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases 2025-04-17 18:00
1